Interleukin-2 and interferon alpha 2 combination

  • Authors:
    • P Pronzato
    • A Vigani
    • F Vaira
    • F Tani
    • M Vanoli
  • View Affiliations

  • Published online on: November 1, 1996     https://doi.org/10.3892/or.3.6.1137
  • Pages: 1137-1139
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

We have studied activity and toxicity of subcutaneous recombinant interleukin-2 and interferon alpha 2b in a series of 14 patients with advanced renal cell carcinoma. No objective response was observed, and the median survival was 16 months (range 3-19); toxicity was acceptable. All the patients had poor prognostic factors and were pretreated with interferon.

Related Articles

Journal Cover

November 1996
Volume 3 Issue 6

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Pronzato P, Vigani A, Vaira F, Tani F and Vanoli M: Interleukin-2 and interferon alpha 2 combination. Oncol Rep 3: 1137-1139, 1996
APA
Pronzato, P., Vigani, A., Vaira, F., Tani, F., & Vanoli, M. (1996). Interleukin-2 and interferon alpha 2 combination. Oncology Reports, 3, 1137-1139. https://doi.org/10.3892/or.3.6.1137
MLA
Pronzato, P., Vigani, A., Vaira, F., Tani, F., Vanoli, M."Interleukin-2 and interferon alpha 2 combination". Oncology Reports 3.6 (1996): 1137-1139.
Chicago
Pronzato, P., Vigani, A., Vaira, F., Tani, F., Vanoli, M."Interleukin-2 and interferon alpha 2 combination". Oncology Reports 3, no. 6 (1996): 1137-1139. https://doi.org/10.3892/or.3.6.1137